Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160593 | 0.76 | GPR3 (0.36) | GPR3CYP1A2CYP2C19CYP2A6CYP19A1 | |
| SCHEMBL938097 | 0.74 | GPR3 (0.44) | GPR3CYP1A2CYP2C19CYP2A6CYP19A1 | |
| SCHEMBL7647965 | 0.63 | GPR3 (0.52) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL7459883 | 0.61 | GPR3 (0.34) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL2344955 | 0.60 | KDM4E (0.38) | GPR3CYP2C19KDM4E | |
| SCHEMBL6894881 | 0.59 | GPR3 (0.37) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL2790587 | 0.58 | SLC6A2 (0.43) | GPR3CYP1A2KDM4E | |
| SCHEMBL4000759 | 0.57 | GPR3 (0.46) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL3466198 | 0.57 | GPR3 (0.46) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL7648214 | 0.57 | GPR3 (0.52) | GPR3CYP1A2CYP2C19CYP2A6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326653-B1 | DETECTION OF THE PRESENCE OF A MICROBE OR RELATED SUBSTANCE AT A LOCATION | CAMBRIDGE MEDITECH LTD (GB) | 2007-07-11 | — | — | EP | claimed |
| US-12006368-B2 | Anti-frizzled antibodies and methods of use | Surrozen Operating, Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240158523-A1 | ANTI-CD40 ANTIBODIES AND METHODS OF USE | APEXIGEN, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11982678-B2 | Ensemble-decision aliquot ranking | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | DAKO DENMARK APS (DK) | 2024-05-09 | — | — | US | disclosed |
| US-20240150458-A1 | ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE | Surrozen Operating, Inc. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240141049-A1 | WNT SURROGATE MOLECULES AND USES THEREOF | Surrozen Operating, Inc. | 2024-05-02 | — | — | US | disclosed |
| US-20240067746-A1 | THERAPEUTIC ANTIBODIES | GLYCONEX INC (TW) | 2024-02-29 | — | — | US | disclosed |
| CN-117561078-A | Biomarkers for assessing risk of developing acute covd-19 and post-acute covd-19 | 奥默罗斯公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230406948-A1 | ANTI-CD40 ANTIBODIES AND METHODS OF USE | APEXIGEN, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-0720744-A1 | AN ASSAY DEVICE | La Mina, Inc. (US) | 1996-07-10 | — | — | EP | disclosed |
| US-5459040-A | Enzyme amplified, complex linked, competitive and non-competitive assays for the detection of metal ions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995026201-A1 | BREVICAN, A GLIAL CELL PROTEOGLYCAN | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-10-05 | — | — | WO | disclosed |
| WO-1995016207-A1 | ASSAY DEVICE WITH A BARRIER FOR REGULATING REAGENT APPLICATION | SMITHKLINE DIAGNOSTICS, INC. (US) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995014926-A1 | ENZYME AMPLIFIED COMPETITIVE AND SANDWICH CHELATION ASSAYS FOR METAL IONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995008117-A1 | AN ASSAY DEVICE | GUIRGUIS RAOUF A (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0643834-A1 | SIMULTANEOUS DRUG TESTING AND FINGERPRINTING ASSAY | LA MINA LTD. (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1994017211-A1 | NON-RADIOACTIVE METHOD FOR DETECTING A LABELLED SEGMENT AND A SOLUTION OR COMPOSITION THEREFOR | WRIGHT DENNIS (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1993006486-A1 | SIMULTANEOUS DRUG TESTING AND FINGERPRINTING ASSAY | LA MINA, LTD. (US) | 1993-04-01 | — | — | WO | disclosed |
| US-4687732-A | COUPLING OF MINUTE QUANITY OF SAMPLE WITH DETECTING AGENT | YALE UNIVERSITY (US) | 1987-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | MICA, CD74, HLA-DRB1 | GPR3 4367/4885CYP1A2 4346/4885CYP2C19 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.